CHICAGO--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present seven studies during the 2016 American Society of Clinical Oncology® (ASCO®) meeting in Chicago from June 3-7, 2016 demonstrating how the use of the immunoSEQ® Assay to characterize the repertoire of T-cells in tumor tissue and in peripheral blood identified prognostic biomarkers and potential biomarkers of response and toxicity in multiple tumor types.
“Both internally and in collaboration, Adaptive actively uses its patented immunosequencing technology to standardize the definition of the immune response to cancer and cancer immunotherapies and to develop biomarkers based on the resulting metrics which have the potential to radically improve patient care.”
Supporting the emerging prognostic potential of immunosequencing, a study by Odunsi, et al. at Roswell Park Cancer Institute will be presented showing the dramatic correlation between immune repertoire metrics, such as T-cell clonality and diversity, and clinical outcome in ovarian cancer. Data highlights using immunosequencing to generate potential biomarkers of response include a study by Funt, et al. from Memorial Sloan Kettering Cancer Center, which utilized the immunoSEQ Assay to quantify tumor infiltrating lymphocytes (TILs) which identified a predictive marker of response to anti-PD-L1 in urothelial cancer. In another study by Zhang, et al. at MD Anderson Cancer Center, the immunoSEQ Assay was used to characterize and compare T-cell receptor beta (TCRB) repertoires in TILs and demonstrates the degree to which TIL heterogeneity is both varied in NSCLC tumors and related to mutational burden.
“Understanding the role of the immune system in combating cancer is rapidly becoming a necessary component of treatment, requiring a new class of biomarkers,” says Dr. Harlan Robins, Chief Scientific Officer and Co-founder of Adaptive Biotechnologies. “Both internally and in collaboration, Adaptive actively uses its patented immunosequencing technology to standardize the definition of the immune response to cancer and cancer immunotherapies and to develop biomarkers based on the resulting metrics which have the potential to radically improve patient care.”
Representatives from Adaptive Biotechnologies will be exhibiting at ASCO booth #2056 to answer questions about its immunosequencing technology.
Oral Presentation Highlights:
Abstract No. 3005: Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab
Presenter: Samual Funt, MD, Memorial Sloan Kettering Cancer center
Oral Abstract Session: Saturday, June 4, 2:39-2:51 p.m.
Location: Hall B1
Poster Presentation Highlights:
Abstract No. 8539 / Poster No. 167: Intra-tumor heterogeneity of T cell receptor repertoire in lung cancers and its association with tumor genomic profile
Presenter: Zhang, et al., MD Anderson Cancer Center
Poster Session: Saturday, June 4, 8:00-11:30 a.m.
Location: Hall A
Abstract No. 3082 / Poster No. 404: Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer
Presenter: Papadopoulous, et al., START Center for Cancer Care
Poster Session: Sunday, June 5, 8:00-11:30 a.m.
Location: Hall A
Abstract No. 3018 / Poster No. 340: Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1
Presenter: Naing, et al., MD Anderson Cancer Center
Poster Session: Sunday, June 5, 8:00-11:30 a.m.
Location: Hall A
Abstract No. 3029 / Poster No. 351: Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients
Presenter: Oh, et al., University of California, San Francisco
Poster Session: Sunday, June 5, 8:00-11:30 a.m.
Location: Hall A
Abstract No. 11017 / Poster No. 143: Using G100 (Glucopyranosyl Lipid A) to transform the sarcoma tumor immune microenvironment
Presenter: Pollack, et al., Fred Hutchinson Cancer Research Center
Poster Session: Monday, June 6, 8:00-11:30 a.m.
Location: Hall A
Abstract No. 5546 / Poster No. 369: Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer
Presenter: Odunsi, et al., Roswell Park Cancer Institute
Poster Session: Monday, June 6, 1:00-4:30 p.m.
Location: Hall A
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit adaptivebiotech.com.
About the immunoSEQ® Platform
Adaptive’s immunoSEQ Platform helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assays can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, immunoSEQ Assays provide quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assays are for research use only and are not for use in diagnostic procedures.
Contacts
Adaptive Biotechnologies
April Falcone
206-939-3835
media@adaptivebiotech.com
